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Abstract. 
Genotyping of allelic variants of Plasmodium falciparum merozoite surface proteins 1 and 2 (msp-1 and msp-2), and 
the glutamate-rich protein is the gold standard for distinguishing reinfections from recrudescences in antimalarial 
drug trials. We compared performance of the recently developed 24-single-nucleotide polymorphism (SNP) 
Barcoding Assay against msp-1 and msp-2 genotyping in a cluster-randomized effectiveness trial of artemether–
lumefantrine and dihydroartemisinin–piperaquine in Malawi. Rates of recrudescence and reinfection estimated by 
the two methods did not differ significantly (Fisher’s exact test; P = 0.887 and P = 0.768, respectively). There was a 
strong agreement between the two methods in predicting treatment outcomes and resolving the genetic complexity 
of malaria infections in this setting. These results support the use of this SNP assay as an alternative method for 
correcting antimalarial efficacy/effectiveness data. 
INTRODUCTION 
In areas of intense malaria transmission, drug-treated malaria patients are at high risk of 
reinfection during long follow-up post-treatment. Without genotyping, pretreatment, and post-
treatment parasites, it is difficult to resolve whether parasites persisting after therapy are due to 
treatment failure (recrudescence) or a new infection (reinfection) and to provide the true risk of 
treatment failure in the population.
1
 
Genotyping of allelic variants of Plasmodium falciparum merozoite surface proteins 1 and 2 
(msp-1 and msp-2), and glutamate-rich protein is the recommended genotyping method.
1,2
 
However, it is labor intensive, has low discriminatory power, and produces results that are often 
ambiguous to interpret and reproduce between laboratories.
3
 Microsatellite genotyping is an 
alternative approach.
4–6
 However, the lack of capillary sequencers to amplify and score 
microsatellites has hampered its wide use. The 24-single-nucleotide polymorphism (SNP) 
Barcoding Assay has shown great potential
7
 but requires expensive reagents and real-time PCR 
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instruments. We compared the performance of the 24-SNP Barcoding Assay and msp-1 and msp-
2 genotyping in an effectiveness trial. 
METHODS 
This study was part of a trial exploring neuro-ototoxic adverse effects in children repeatedly 
treated with artemisinin-based combination therapies (NCT01038063). Ethical approvals were 
obtained from Liverpool School of Tropical Medicine Research Ethics Committee (Protocol 
09.07), University of Malawi College of Medicine Research and Ethics Committee (Protocol 
P.10/08/707), and Malawi’s Pharmacy, Medicines and Poisons Board (Protocol 
PMPB/CTRC/III/1211200904). 
Children with uncomplicated malaria were randomized to receive artemether–lumefantrine 
(AL) or dihydroartemisinin–piperaquine (DHA-PPQ) and followed up for 42 days. A filter paper 
blood sample was collected before treatment and 42 days posttreatment regardless of day 42 
slide positivity. 
To determine if a child had recurrent parasitemia on day 42, parasite DNA was extracted 
from d0 and d42 samples using DNA Mini Kits (Qiagen, United Kingdom) and genotyped using 
the 24-SNP Barcoding Assay, and msp-1 and msp-2 genotyping as previously described.
2,7
 
Investigators genotyping samples were blinded to d42 slide positivity. Infections with  2 and  
1 heterozygous SNPs were classified as multiple- and single-haplotype infections, respectively.
8
 
We performed a loci resampling analysis in GenClone v.2.0
9
 to determine the minimum number 
of SNPs required to capture full haplotypic diversity amongst single-haplotype infections 
sampled. 
Recurrent parasitemia was considered a reinfection if d0 and d42 parasites were genetically 
distinguishable; otherwise, it was deemed a reinfection. All proportions and their binomial exact 
95% confidence intervals (CIs) were computed using Stata version 11.0 (College Station, TX). 
RESULTS AND DISCUSSION 
We evaluated 109 pairs of filter paper blood samples collected on days 0 and 42. Of these, 
65% (N = 71) showed no detectable parasite DNA on d42, whereas 38 had recurrent d42 
parasitemia. Detailed effectiveness data for the trial will be presented elsewhere (Terlouw et al., 
unpublished data). Genotype data and treatment outcomes for 38 patients with recurrent 
parasitemia are shown in Supplemental Tables 1 and 2, whereas genotype data for 71 patients 
with no detectable parasite DNA on d42 are shown in Supplemental Tables 3 and 4. A sample 
size of 38 recurrent infections allows us to detect a 34% difference in rates of reinfection 
estimated by the two methods with 80% power and 95% CI. Repeat msp-1 and msp-2 genotyping 
was performed on ?20% of samples because of contamination in the negative control or failure 
to amplify some loci during the initial genotyping attempt. However, genotyping failure rate for 
the 24-SNP Barcoding Assay was low with > 95% of SNP assays yielding data at the first 
genotyping attempt and < 5% allele drop out per sample. 
Rates of reinfection and treatment failure did not differ significantly between methods 
(Fisher’s exact test; P = 0.887 and P = 0.768, respectively) (Figure 1A). There was a strong 
concordance between the two methods in predicting treatment responses among all the 109 
patients evaluated and in 38 patients with recurrent d42 parasitemia (Figure 1B). There was also 
a strong agreement between the two methods in determining the clonality of parasite samples 
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(whether a sample is monoclonal or multiclonal) (Figure 1B). The proportion of multiclonal 
samples was similar between methods (Supplemental Figure 1). Relationships among 62 
monoclonal samples identified using the 24-SNP Barcoding Assay are shown in the phylogenetic 
tree (Supplemental Figure 2). We observed a modest concordance of 56.5% (binomial exact 95% 
CI: 48.0–64.6) between the two methods in estimating the multiplicity of infection for individual 
samples (Figure 1B). This presumably reflects subtle differences in the resolution power of the 
two assays. Treatment failure rate was 6.4% by the 24-SNP Barcoding Assay and 4.6% by msp-1 
and msp-2 genotyping (P = 0.768). The small discrepancy between recrudescence rates estimated 
by the two methods resulted from classifying two recurrent infections, which were otherwise 
considered as reinfections by msp-1 and msp-2 genotyping, because of treatment failures caused 
by using SNP genotyping (Supplemental Tables 1 and 2). Treatment failures observed may be 
explained by nonadherence, pharmacokinetic variations, parasite resistance, and/or drug loss 
through vomiting. Study participants were given a full course of AL or DHA-PPQ with only the 
first dose given under supervision. This may promote noncompliance but accurately represents 
how drugs might be used in the community. In a previous study, 79% and 88% of AL- and 
DHA-PPQ–treated patients complied with recommended drug dosing schedules, respectively.13 
High rates of reinfection are of concern. Both genotyping methods showed that ?30% of 
children treated for malaria are reinfected within 42 days post-treatment. This finding indicates 
that the intensity of transmission is very high. Compared with DHA-PPQ, AL is associated with 
higher risk of recurrent parasitemia
14,15
 attributable to shorter elimination half-life of the partner 
drug, lumefantrine. However, an ACT such as DHA-PPQ, with a long elimination half-life of the 
partner drug, may still fail to protect against reinfections if overwhelmed by intense transmission 
levels.
14
 To help reduce malaria transmission, new transmission reduction strategies such as mass 
drug administration, focal screening and treatment, or mass screening and treatment should be 
considered.
16
 
Our findings clearly demonstrate that the 24-SNP Barcoding Assay performs msp-1 and msp-
2 genotyping. The main advantage of msp-1 and msp-2 genotyping is its low cost. We estimate 
that genotyping costs $11.45/sample versus $3.60/sample for the 24-SNP Barcoding Assay and 
msp-1 and msp-2 genotyping, respectively. Unlike the 24-SNP Barcoding Assay that relies on 
expensive real-time PCR instruments, msp-1 and msp-2 genotyping uses relatively inexpensive 
and common laboratory equipment such as gel electrophoresis equipment and UV 
transilluminators to genotype samples. Nonetheless, inherent limitations of msp-1 and msp-2 
genotyping outweigh its low-cost attractiveness. This method is extremely labor intensive, prone 
to contamination, has limited resolution power, and generates data that are often ambiguous to 
interpret and reproduce between different laboratories because of dependency on visual 
interpretation of allele migration patterns on agarose gels. In contrast, the 24-SNP Barcoding 
Assay is less labor intensive, has better resolution power, and generates data that are easy to 
score and reproduce between laboratories. The 24-SNP Barcoding Assay has better 
discriminatory power because it interrogates 24 highly polymorphic SNPs rather than two msp-1 
and msp-2 loci. Because of its excellent attributes, the 24-SNP Barcoding Assay should be 
adopted as an alternative genotyping method. However, high cost could derail its adoption. We 
investigated whether an abbreviated SNP set with fewer SNPs could equally identify all parasite 
haplotypes as 24 SNPs. Our results indicate that 17 SNPs, irrespective of their minor allele 
frequencies within the 62 single-haplotype infections identified, can reliably capture all parasite 
haplotypes identified by 24 SNPs (Figure 2, Supplemental Table 1). Our data also indicate that if 
SNPs with a high minor allele frequency ( 0.30) are selected, only 12 of these are required to 
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identify all parasite haplotypes (Figure 2, Supplemental Table 1). It would cost $5.73 to 
genotype a single sample using the abbreviated SNP assay. Reduction in cost and availability of 
real-time instruments in most countries make the abbreviated SNP assay attractive and feasible 
to adopt. 
CONCLUSION 
Our results demonstrate that the 24-SNP Barcoding Assay performs msp-1 and msp-2 
genotyping and should be adopted as an alternative method for PCR adjustment of antimalarial 
effectiveness/efficacy data. Resource-constrained laboratories should consider deploying an 
abbreviated SNP assay comprising 12 SNPs with high minor allele frequency to reduce 
genotyping costs while maintaining high assay resolution. Each continent must identify SNPs 
with high minor allele frequency to select informative SNPs. 
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FIGURE 1. Comparison of two genotyping methods. (A) Rates of reinfection and recrudescence estimated by the 24-
single-nucleotide polymorphism (SNP) Barcoding Assay and merozoite surface proteins 1 and 2 (msp-1 and msp-2) 
genotyping. The number on top of each bar represents number of patients with a defined treatment outcome out of 
109 patients evaluated. Rates of reinfection and recrudescence estimated by the two methods were similar (Fisher’s 
exact test; P = 0.887 and P = 0.768, respectively). (B) Agreement between methods in determining treatment 
outcomes, infection clonality, and multiplicity of infection. Figures on top of each bar are percentages of concordant 
samples out of all samples analyzed in square brackets. Multiplicity of infection was determined from SNP data of 
each sample using COIL
17
 and from msp-1 and msp-2 data as the highest number of alleles observed at the most 
diverse locus. In both A and B, error bars are binomial exact 95% confidence intervals. 
FIGURE 2. Resolution power of the 24-single-nucleotide polymorphism (SNP) Barcoding Assay inferred from SNP 
resampling. The gray line shows maximum haplotype diversity captured when all 24 SNPs are used to characterize 
diversity, whereas the black line indicates diversity identified when only SNPs with a high minor allele frequency ( 
0.30) are used. Error bars are 95% confidence intervals for the mean number of parasite haplotypes identified. 
Diversity plateaus after 17 and 12 loci if all 24 SNPs and SNPs with high minor allele frequency are used to 
genotype samples, respectively, indicating the assay’s sufficient discriminatory power. 
SUPPLEMENTAL FIGURE 1. Proportion of multiclonal samples estimated by the 24-single-nucleotide polymorphism 
(SNP) Barcoding Assay compared with that determined by merozoite surface proteins 1 and 2 (msp-1 and msp-2) 
genotyping. The proportion of multiclonal samples in a combined set of pretreatment and posttreatment samples (N 
= 147) and in pretreatment samples alone (N = 109) did not differ significantly between the two methods (Fisher’s 
exact test; P = 0.186 and P = 0.094, respectively). Error bars are binomial exact 95% confidence intervals for the 
proportion of multiclonal samples. The number on top of each bar represents the number of multiclonal samples 
detected by each of the two genotyping methods. For example, the proportion of pretreatment samples deemed to be 
multiclonal by the 24-SNP Barcoding Assay equals 61/109 = 0.560. 
SUPPLEMENTAL FIGURE 2. UPGMA tree showing relationships between parasite haplotypes identified by the 24-
single-nucleotide polymorphism (SNP) Molecular Barcode Assay. We computed the proportion of SNP alleles 
shared (ps) between all pairwise comparisons of single-haplotype infections sampled and clustered infections on the 
UPGMA tree based on the genetic distance metric, 1-ps, using PHYLIP.
18
 Only data for single-haplotype parasite 
infections are shown because allele-sharing can be unambiguously computed. Pretreatment episodes of parasitemia 
in patients 20 and 71 (i.e., 20d0 and 71d0) have the same parasite DNA fingerprint as their respective posttreatment, 
episodes 20d42 and 71d42. Therefore, recurrent episodes of parasitemia in patients 20 and 71 are treatment failures. 
On the other hand, posttreatment episodes of parasitemia in patients 18 and 40 (i.e., 18d42 and 40d42) are 
genetically different from pretreatment episodes (18d0 and 40d0). These are a classical case of reinfection. 
SUPPLEMENTAL REFERENCE 
<bok>18. Felsenstein J, 1993. PHYLIP (Phylogeny Inference Package) v.3.57. Distributed by 
the Author. Seattle, WA: Department of Genetics, University of Washington.</bok> 
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SUPPLEMENTAL TABLE 1 
SNP data for recurrent infections 
Pati
ent 
ID 
D
ay 
SN
P1 
SN
P2 
SN
P3 
SN
P4 
SN
P5 
SN
P6 
SN
P7 
SN
P8 
SN
P9 
SNP
10 
SNP
11 
SNP
12 
SNP
13 
SNP
14 
SNP
15 
SNP
16 
SNP
17 
SNP
18 
SNP
19 
SNP
20 
SNP
21 
SNP
22 
SNP
23 
SNP
24 
Treatm
ent 
outcom
e 
No. of 
heterozy
gous 
SNPs 
Clona
lity 
M
OI 
95% 
confid
ence 
interva
l for 
MOI 
Probab
ility 
for 
MOI 
103
d0 
0 T A C C C G A G A T C G T A C C C T C A A T T G – 0 S 1 [1, 1] 1 
103
d42 
42 – A 
C/
T 
C/
T 
C/
G 
G G G A T C/T A/G T C C C C A/T C A A/C C G G 
Reinfe
ction 
7 M 2 [2, 2] 0.9954 
10d
0 
0 T A C 
C/
T 
C/
G 
G A G 
A/
T 
C C G C A C C C/T A A G C T T G – 4 M 2 [1, 2] 0.8355 
10d
42 
42 T A C 
C/
T 
C/
G 
G A G 
A/
T 
C C G C A C C C/T A A G C T T G 
Treatm
ent 
failure 
4 M 2 [1, 2] 0.8355 
11d
0 
0 T A 
C/
T 
C/
T 
C 
C/
G 
A/
G 
A/
G 
A/
T 
C C A/G T A C C C/T A/T A A/G A/C C/T T G – 12 M 2 [2, 4] 0.5617 
11d
42 
42 T A T T C C G G T C T G C A A C C A A G C C T G 
Reinfe
ction 
0 S 1 [1, 1] 1 
12d
0 
0 T A T T C G A G T C C G C A C C C A C G A C T G – 0 S 1 [1, 1] 1 
12d
42 
42 T A 
C/
T 
T C 
C/
G 
A/
G 
G 
A/
T 
C/T C/T A/G C/T A C A/C C/T A A A/G A/C C/T G/T G 
Reinfe
ction 
14 M 3 [3, 5+] 0.5103 
16d
0 
0 T A 
C/
T 
T C 
C/
G 
A G 
A/
T 
T C A/G C/T A A/C A/C C A A A/G C T T G – 8 M 2 [2, 3] 0.9369 
16d
42 
42 C A C T G C G G A T T G C A A C C T C G C C – G 
Reinfe
ction 
0 S 1 [1, 1] 1 
17d
0 
0 C A 
C/
T 
C/
T 
C/
G 
C/
G 
A/
G 
G A C/T C/T A/G C/T A/C A/C A/C C/T A/T A G A/C C/T T G – 16 M 4 [3, 5+] 0.4335 
17d
42 
42 C A C T G C A – A C/T C/T A T A/C C C T A A G A/C T T G 
Treatm
ent 
failure 
4 M 2 [1, 2] 0.8514 
18d 0 – – C – – C A G A T T – T C A – C – A A C C T G – 0 S 1 [1, 1] 0.9998 
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0 
18d
42 
42 T A C T G C G G A C C G C A A C T A C G C C T G 
Reinfe
ction 
0 S 1 [1, 1] 1 
20d
0 
0 T A T T C G A G A T T G C A A C C A A G C T T G – 0 S 1 [1, 1] 0.9999 
20d
42 
42 T A T T C G A G A T T G C A A C C A A G C T T G 
Treatm
ent 
failure 
0 S 1 [1, 1] 0.9999 
2d0 0 T A 
C/
T 
T C C A G A C/T C/T A/G C A C C C A A G A T G G – 4 M 2 [2, 2] 0.9719 
2d4
2 
42 T A C T C C A G A T C A C A C A/C T T A G A T T G 
Reinfe
ction 
1 S 1 [1, 1] 0.9996 
30d
0 
0 T A C 
C/
T 
C C A 
A/
G 
A T C/T G C/T A C C C A/T A A A/C C/T G/T G – 8 M 2 [2, 3] 0.9416 
30d
42 
42 C A C T C C A G A T C G C A C C T A A G A C G G 
Reinfe
ction 
0 S 1 [1, 1] 1 
31d
0 
0 T A C C C C G G A T – A C A C C C A A G C C T G – 0 S 1 [1, 1] 1 
31d
42 
42 T A T T C C A G A T C G C A/C C C C A/T A A/G A T T G 
Reinfe
ction 
3 M 1 [1, 2] 0.6299 
32d
0 
0 C A 
C/
T 
T C C 
A/
G 
G A C/T C G C A A C T A A A/G C C/T T G – 5 M 2 [2, 2] 0.993 
32d
42 
42 T A C T 
C/
G 
G 
A/
G 
G T T C/T A C/T A/C C A C/T A A G A/C C/T T G 
Reinfe
ction 
8 M 2 [2, 2] 0.9686 
37d
0 
0 C A 
C/
T 
C/
T 
C 
C/
G 
A/
G 
G A T C G C A A/C C C/T A/T A A C C/T T G – 8 M 2 [2, 3] 0.9497 
37d
42 
42 
C/
T 
A 
C/
T 
T C 
C/
G 
A/
G 
G 
A/
T 
C/T C/T A/G C A A/C C C A A G A/C C/T G/T G 
Reinfe
ction 
12 M 3 [2, 4] 0.6139 
40d
0 
0 T A C T C C G G A C C A C A C C C T A A A C G G – 0 S 1 [1, 1] 1 
40d
42 
42 T A T T C G A G A T T G C A C A C T A G C T G G 
Reinfe
ction 
0 S 1 [1, 1] 1 
47d
0 
0 C A C T C G G G A T C A C A C C C A A G A/C C/T G/T G – 3 M 1 [1, 2] 0.6478 
47d
42 
42 T A C C G G G G T C T G C A A C C A C G C T T G 
Reinfe
ction 
0 S 1 [1, 1] 1 
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48d
0 
0 T A C C G C G G A C/T T A T A A C C A A A C C T G – 1 S 1 [1, 1] 0.9999 
48d
42 
42 T A C T C 
C/
G 
A G A C/T T A C – – – – – – – – – – G 
Reinfe
ction 
2 M 2 [1, 3] 0.8519 
49d
0 
0 T A C 
C/
T 
C G 
A/
G 
G A C/T C/T A C A C C C/T A A A/G C C T G – 6 M 2 [2, 2] 0.9889 
49d
42 
42 T A 
C/
T 
T 
C/
G 
C/
G 
G G A C T A C A A A/C C/T A A A/G C C T G 
Treatm
ent 
failure 
6 M 2 [2, 2] 0.992 
4d0 0 T A C C C C 
A/
G 
G A T T G C C C C C T A A/G C T T G – 2 M 1 [1, 1] 0.9857 
4d4
2 
42 T A C T C C 
A/
G 
G A C T G C A A C C/T T C A/G A C/T G/T G 
Reinfe
ction 
5 M 2 [2, 2] 0.9915 
53d
0 
0 C A 
C/
T 
T C 
C/
G 
A G 
A/
T 
C/T C/T A/G T A C C C A/T A A/G C T T G – 8 M 2 [2, 3] 0.9473 
53d
42 
42 
C/
T 
A T 
C/
T 
C/
G 
G A G A T C G C C A A/C C A C G A/C C T G 
Reinfe
ction 
5 M 2 [2, 2] 0.976 
55d
0 
0 – A C – C C A G A C – – C A C A C/T – A G C T T G – 1 S 1 [1, 1] 0.9906 
55d
42 
42 T A C T C 
C/
G 
A/
G 
G T C/T T G T A A A C T A G A/C C/T T G 
Reinfe
ction 
5 M 2 [2, 2] 0.9909 
56d
0 
0 T 
A/
G 
C/
T 
T C 
C/
G 
A/
G 
G 
A/
T 
C/T C/T A/G C/T A C A/C C A/T A A/G A/C C/T G/T G – 15 M 3 [3, 5+] 0.4084 
56d
42 
42 C A 
C/
T 
C/
T 
C 
C/
G 
A/
G 
G 
A/
T 
T C/T G C/T A C C C/T A A A/G A/C C/T T G 
Reinfe
ction 
11 M 2 [2, 3] 0.5907 
57d
0 
0 T A C C C G A G A C T A C A C C C A A G A C T G – 0 S 1 [1, 1] 1 
57d
42 
42 T A C T C G A G A C T G C A A C C T C G A T G/T G 
Reinfe
ction 
1 S 1 [1, 1] 0.9983 
59d
0 
0 C 
A/
G 
C/
T 
T 
C/
G 
C/
G 
A/
G 
G 
A/
T 
C/T C A/G C/T A/C C A/C C/T A/T A A/G A/C C/T T G – 16 M 4 [3, 5+] 0.3749 
59d
42 
42 C 
A/
G 
C T – G 
A/
G 
A/
G 
A C/T C/T A/G C/T C C A/C C A/T A G A/C C/T G/T G 
Treatm
ent 
failure 
12 M 2 [2, 4] 0.4954 
5d0 0 C A 
C/
T 
C/
T 
C 
C/
G 
A 
A/
G 
A C/T C/T A/G C A/C A/C A/C C/T A A G A/C C/T G/T G – 14 M 3 [2, 5+] 0.5362 
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5d4
2 
42 T A C T C C G G T T C/T A C/T A A C T T C G C T T G 
Reinfe
ction 
2 M 1 [1, 1] 0.994 
60d
0 
0 C A C 
C/
T 
C C 
A/
G 
G A C/T T A/G C A C A/C C/T A A G A/C C/T G/T G – 9 M 2 [2, 3] 0.8293 
60d
42 
42 
C/
T 
A 
C/
T 
T 
C/
G 
C/
G 
A/
G 
G A C/T C/T A/G C/T A/C C A/C C/T A/T A A/G A/C C/T G/T G 
Treatm
ent 
failure 
17 M 5 [3, 5+] 0.4997 
61d
0 
0 T A T T 
C/
G 
C G G A C/T T G C A C A C A/T A G A/C T T G – 4 M 2 [1, 2] 0.9096 
61d
42 
42 C A C T C C A G A T T G T A A C T T A A A C G G 
Reinfe
ction 
0 S 1 [1, 1] 1 
62d
0 
0 T A T C G 
C/
G 
G G T T C A T A C C T A A G C C/T T G – 2 M 1 [1, 1] 0.9998 
62d
42 
42 
C/
T 
A C 
C/
T 
C/
G 
C A G A C/T C/T A C A C C T A C A/G A/C C/T G/T G 
Reinfe
ction 
9 M 2 [2, 3] 0.9053 
63d
0 
0 C A C T G C G G A T T A T A A C C A A/C G C T T G – 1 S 1 [1, 1] 0.9996 
63d
42 
42 C A C T 
C/
G 
C/
G 
A G 
A/
T 
C/T T A T C C C T A/T C G C T G/T G 
Reinfe
ction 
6 M 2 [2, 2] 0.9965 
64d
0 
0 T A T T C C G G T C/T T G T A A/C C C A C G A C/T T G – 3 M 1 [1, 2] 0.8251 
64d
42 
42 T A C T 
C/
G 
C A G A C/T T G C C C A/C T A A G C C/T T G 
Reinfe
ction 
4 M 2 [1, 2] 0.926 
71d
0 
0 C A C T G G A G A T T A T C A A C T C G A T T G – 0 S 1 [1, 1] 1 
71d
42 
42 C A C T G G A G A T T A T C A A C T C G A T T G 
Treatm
ent 
failure 
0 S 1 [1, 1] 1 
72d
0 
0 T A C T C 
C/
G 
G G A T C/T G C A A/C C T A/T A/C G A/C T T G – 6 M 2 [2, 2] 0.975 
72d
42 
42 T A C T C C A G A T C G C A/C A C T A/T A A/G C T T G 
Reinfe
ction 
3 M 2 [1, 2] 0.5512 
81d
0 
0 T A 
C/
T 
C/
T 
C/
G 
C/
G 
A 
A/
G 
A C/T C/T G C/T A/C C A/C C/T A A A/G A/C C G/T G – 14 M 3 [2, 4] 0.5971 
81d
42 
42 C A C C C C A G T T T G C C A C C A C G A T T G 
Reinfe
ction 
0 S 1 [1, 1] 1 
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87d
0 
0 C A C T C C A A A T T A C C C C C T C G C T G G – 0 S 1 [1, 1] 1 
87d
42 
42 T A T C C G G G 
A/
T 
C/T C/T A T A C A T A A G A/C C/T T G 
Reinfe
ction 
5 M 2 [1, 2] 0.9003 
88d
0 
0 C A T T C C A G 
A/
T 
T C – T C A C C A A A/G A/C T T G – 3 M 1 [1, 2] 0.8727 
88d
42 
42 T A C T 
C/
G 
C A G T C T A/G C/T A/C A/C C C T A A/G A/C T T G 
Reinfe
ction 
7 M 2 [2, 2] 0.9667 
89d
0 
0 T A C T C C A G A T T G C A C C C T C G C C G G – 0 S 1 [1, 1] 1 
89d
42 
42 T A T T G C A G A C T A C A A C T A C G C T G G 
Reinfe
ction 
0 S 1 [1, 1] 1 
8d0 0 T A C T G G A G A T T G C A A C C A A G A T T G – 0 S 1 [1, 1] 0.9999 
8d4
2 
42 T A C C G C A G T T T G C A C C C A/T A A/G C C T G 
Reinfe
ction 
2 M 1 [1, 1] 0.9953 
94d
0 
0 
C/
T 
A/
G 
C/
T 
C/
T 
C/
G 
C/
G 
A/
G 
G 
A/
T 
C/T C/T A/G C/T A C C C/T A/T A A/G A/C C/T T G – 17 M 4 [3, 5+] 0.4262 
94d
42 
42 T A C T C C 
A/
G 
G A T T G C A A A C T A G A T G G 
Reinfe
ction 
1 S 1 [1, 1] 1 
98d
0 
0 – – 
C/
T 
– 
C/
G 
C/
G 
– – T C T A/G T A A A/C C/T A/T A A/G A/C T G G – 9 M 2 [2, 3] 0.79 
98d
42 
42 – A – – C G – G T C T G C A/C C C T A/T C G A C G G 
Reinfe
ction 
2 M 1 [1, 1] 0.9872 
DD
2 
N/
A 
T A T C C G G A T T T A T C A A T A C A A C G T N/A 0 S 1 [1, 1] 1 
HB3 
N/
A 
T G C C C C A G A T C A C A A C T A A G T T T T N/A 0 S 1 [1, 1] 1 
K1 
N/
A 
C G C T C G G A T T T A T C C C T A C G C C G T N/A 0 S 1 [1, 1] 1 
R03
3 
N/
A 
C A T T G C A G A C T – C A C C T T A G A T T G N/A 0 S 1 [1, 1] 1 
W2 
N/
A 
T A T C C G G A T T T A T C A A T A C A A C G T N/A 0 S 1 [1, 1] 1 
3D7 
N/
A 
C G C T C C G G A C T G C A C C C A A G A T T G N/A 0 S 1 [1, 1] 1 
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N/A = not applicable; SNP = single-nucleotide polymorphism. For each patient, both the d0 and d42 filter paper samples were genotyped using the 24-SNP 
Barcoding Assay (Daniels et al.).
7
 Treatment outcomes inferred from genotyping the d0 and d42 samples are coded as “Reinfection” and “Treatment failure.” 
Only data for 38 recurrent infections are shown. “–” denotes that an allele was not detected. No. of heterozygous SNPs is the number of loci out of the 24 
genotyped that carry both alternate SNP alleles. Clonality denotes the genetic complexity of an infection, that is, whether the infection contains multiple-parasite 
haplotypes (M) or a single-parasite haplotype (S). MOI = multiplicity of infection as determined by the maximum likelihood method called COIL (Galinsky et 
al.).
17
 Twelve SNPs highlighted in blue are proposed for the abbreviated SNP assay. Highlighted in green at the bottom of the table are SNP data for laboratory 
control parasites. Highlighted in red are alleles that allowed to conclude that the outcome for the paired samples was a “Reinfection.” 
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SUPPLEMENTAL TABLE 2 
Msp-1 and msp-2 genotype data for recurrent infections 
Patient 
ID 
Day 
MAD 
20 
MAD 20 
fragment 
size 
K1 
K1 
fragment 
size 
RO33 
R033 
fragment 
size 
3D7/IC 
3D7/IC 
fragment 
size 
FC27 
FC27 
fragment 
size 
Treatment 
outcome 
Clonality MOI 
103d0 0 – – † 200 – – †† 500; 600 † 300 – M 2 
103d42 42 † 200 † 250 – – † 500 † 400 Reinfection M 2 
10d0 0 †† 200; 300 † 150 – – † 500 † 300 – M 3 
10d42 42 †† 200; 300 † 150 – – † 500 † 300 
Treatment 
failure 
M 3 
11d0 0 † 300 † 200 – – †† 300; 500 † 450 – M 2 
11d42 42 – – † 200 – – † 600 – – Reinfection S 1 
12d0 0 † 200 – – – – – – † 500 – S 1 
12d42 42 – – † 250 † 160 ††† 
300; 500; 
700 
††† 
400; 300; 
500 
Reinfection M 3 
16d0 0 – – † 200 – – † 350 † 400 – M 2 
16d42 42 † 200 – – – – † 500 – – Reinfection S 1 
17d0 0 † 250 †† 200; 300 † 160 †† 350; 400 – – – M 3 
17d42 42 † 200 † 250 † 160 † 500 – – Reinfection M 3 
18d0 0 – – – – † 160 † 550 – – – S 1 
18d42 42 † 200 – – – – † 300 – – Reinfection S 1 
20d0 0 † 200 – – – – – – † 300 – S 1 
20d42 42 † 200 – – – – – – † 300 
Treatment 
failure 
S 1 
2d0 0 † 200 † 200 – – † 500 – – – M 2 
2d42 42 – – – – † 160 – – † 300 Reinfection S 1 
30d0 0 † 200 † 200 – – † 500 †† 200; 300 – M 2 
30d42 42 † 200 – – – – † 500 – – 
Treatment 
failure 
S 1 
31d0 0 – – † 200 – – – – † 350 – S 1 
31d42 42 – – †† 200; 300 – – †† 300; 500 †† 200; 300 Reinfection M 2 
32d0 0 † 200 † 300 † 160 ††† 
300; 500; 
600 
††† 
300; 400; 
450 
– M 3 
32d42 42 – – † 250 – – – – † 400 Reinfection S 1 
37d0 0 – – † 150 – – † 500 † 250 – M 2 
37d42 42 † 150 † 250 – – † 400 † 350 Reinfection M 2 
40d0 0 – – – – † 160 – – † 350 – S 1 
40d42 42 – – † 200 – – – – † 300 Reinfection S 1 
47d0 0 † 200 – – – – † 250 † 250 – M 2 
47d42 42 – – † 200 – – † 500 – – Reinfection S 1 
48d0 0 – – † 200 – – – – † 220 – S 1 
48d42 42 † 200 – – – – † 500 † 350 Reinfection M 2 
49d0 0 – – † 200 – – † 500 † 400 – M 2 
49d42 42 – – † 250 – – † 600 † 250 Reinfection M 2 
4d0 0 – – – – † 160 † 600 † 400 – M 2 
4d42 42 – – – – † 160 † 350 † 300 Reinfection M 2 
Page 14 of 39 
53d0 0 † 200 † 250 – – † 500 † 400 – M 2 
53d42 42 † 200 †† 200; 300 – – † 500 – – Reinfection M 2 
55d0 0 †† 200; 300 – – – – † 700 † 350 – M 2 
55d42 42 † 200 † 300 – – † 600 † 300 Reinfection M 2 
56d0 0 † 200 † 200 – – †† 300; 400 †† 350; 450 – M 2 
56d42 42 † 200 † 250 – – † 400 – – Reinfection M 2 
57d0 0 – – – – † 160 † 500 †† 300; 500 – M 2 
57d42 42 – – – – † 160 – – † 300 
Treatment 
failure 
S 1 
59d0 0 † 200 – – – – † 600 † 400 – M 2 
59d42 42 – – † 250 – – † 500 † 300 Reinfection M 2 
5d0 0 – – †† 200; 250 – – – – † 350 – M 2 
5d42 42 † 200 † 300 – – † 500 † 400 Reinfection M 2 
60d0 0 † 200 † 300 – – † 600 – – – M 2 
60d42 42 – – † 200 – – – – † 300 Reinfection S 1 
61d0 0 † 200 – – – – † 600 ††† 
300; 350; 
400 
– M 3 
61d42 42 – – † 200 – – – – † 350 Reinfection S 1 
62d0 0 †† 200; 300 † 300 – – – – † 400 – M 2 
62d42 42 † 250 – – – – † 500 † 350 Reinfection M 2 
63d0 0 – – † 250 – – † 700 † 350 – M 2 
63d42 42 †† 200; 300 † 200 – – † 500 – – Reinfection M 2 
64d0 0 – – – – † 160 † 500 † 600 – M 2 
64d42 42 – – – – † 160 † 600 – – Reinfection S 1 
71d0 0 † 200 – – – – † 500 † 300 – M 2 
71d42 42 † 200 – – – – † 500 † 300 
Treatment 
failure 
M 2 
72d0 0 – – † 200 – – † 700 † 450 – M 2 
72d42 42 † 200 † 250 – – † 500 † 400 Reinfection M 2 
81d0 0 †† 200; 250 † 250 – – – – † 400 – M 2 
81d42 42 – – – – † 160 – – † 300 Reinfection S 1 
87d0 0 † 200 – – – – † 500 – – – S 1 
87d42 42 – – † 250 – – ††† 
400; 450; 
500 
† 350 Reinfection M 3 
88d0 0 † 200 † 300 – – †† 400; 450 † 250 – M 2 
88d42 42 – – † 200 – – † 700 † 200 Reinfection M 2 
89d0 0 † 200 – – – – † 450 †† 200; 250 – M 2 
89d42 42 † 300 † 300 – – † 350 †† 200; 300 Reinfection M 2 
8d0 0 – – † 150 – – † 500 – – – S 1 
8d42 42 † 250 – – – – † 700 † 350 Reinfection M 2 
94d0 0 † 200 †† 200; 250 – – † 300 †† 350; 450 – M 2 
94d42 42 – – † 300 – – – – † 400 Reinfection S 1 
98d0 0 † 250 † 200 – – †† 400; 500 † 300 – M 2 
98d42 42 † 200 – – – – † 600 † 450 Reinfection M 2 
DD2 N/A † 220 – – – – – – † 400 N/A S 1 
HB3 N/A † 180 – – – – – – † 300 N/A S 1 
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K1 N/A – – † 180 – – – – † 380 N/A S 1 
R033 N/A – – – – † 160 † 480 – – N/A S 1 
W2 N/A † 220 – – – – – – † 400 N/A S 1 
3D7 N/A – – † 250 – – † 500 – – N/A S 1 
For each patient, both the d0 and d42 filter paper samples were genotyped at msp-1 and msp-2 loci (Snounou et al.).
2
 
Only data for 38 recurrent infections are shown. “†” denotes that one allele is present at a locus, whereas “–” shows 
that it is absent. If two alleles are present, the data are shown as shown as “††” and “†††” if three are present, etc. 
Allele size is the approximate molecular size in bp of an msp-1 or msp-2 fragment detected. Treatment outcomes 
inferred from genotyping the d0 and d42 samples are coded as “Reinfection” and “Treatment failure.” Clonality 
denotes the genetic complexity of an infection, that is, whether the infection contains multiple-parasite haplotypes 
(M) or a single-parasite haplotype (S). N/A = not applicable. Multiplicity of infection (MOI) is an estimate of the 
minimum number of parasite haplotypes present within an infection and was determined as the highest number of 
alleles observed at the most diverse locus. Highlighted in green at the bottom of the table are msp-1 and msp-2 
genotype data for laboratory control parasites. Highlighted in red are alleles that allowed to conclude that the 
outcome for the paired samples was a “Reinfection.” 
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SUPPLEMENTAL TABLE 3 
SNP data for patients with no detectable d42 parasitemia 
Pati
ent 
ID 
D
ay 
SN
P1 
SN
P2 
SN
P3 
SN
P4 
SN
P5 
SN
P6 
SN
P7 
SN
P8 
SN
P9 
SN
P10 
SN
P11 
SN
P12 
SN
P13 
SN
P14 
SN
P15 
SN
P16 
SN
P17 
SN
P18 
SN
P19 
SN
P20 
SN
P21 
SN
P22 
SN
P23 
SN
P24 
Treatment 
outcome 
No. of 
hetero
zygou
s 
SNPs 
Clon
ality 
M
OI 
95% 
confid
ence 
interva
l for 
MOI 
Probab
ility 
for 
MOI 
100
d0 
0 T 
A/
G 
C/
T 
C/
T 
C 
C/
G 
A/
G 
G A C/T C/T G C A A/C A/C C/T A A G A/C C/T G/T G – 13 M 3 [2, 4] 0.6102 
100
d42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
response 
– – – – – 
101
d0 
0 T A C C C C A G A C T A T A A A C A A A A C G G – 0 S 1 [1, 1] 1.0000 
101
d42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
response 
– – – – – 
102
d0 
0 T A C T C C 
A/
G 
G A T C G T A A C T A A G A/C C/T T G – 3 M 2 [1, 2] 0.5327 
102
d42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
response 
– – – – – 
104
d0 
0 T A 
C/
T 
T 
C/
G 
C 
A/
G 
A/
G 
A/
T 
C/T C G C A C A/C C/T A/T A/C A/G A/C C/T G/T G – 14 M 3 [2, 5+] 0.5642 
104
d42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
response 
– – – – – 
105
d0 
0 T A C T G G A G A T C A T C C C T T A A C T G G – 0 S 1 [1, 1] 1.0000 
105
d42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
– – – – – 
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ical 
response 
106
d0 
0 T A C T C C G G A T T G C A A A C T A G A T T G – 0 S 1 [1, 1] 1.0000 
106
d42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
response 
– – – – – 
13d
0 
0 T A T T C C A G A C T G C C A C C T C A A C T G – 0 S 1 [1, 1] 1.0000 
13d
42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
response 
– – – – – 
14d
0 
0 T A T C G C A A A T C G T A A C C T C A A C G G – 0 S 1 [1, 1] 1.0000 
14d
42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
response 
– – – – – 
15d
0 
0 C A C 
C/
T 
C C 
A/
G 
G A C/T T A/G C/T A C A/C C T A A/G C T T G – 7 M 2 [2, 2] 0.9757 
15d
42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
response 
– – – – – 
19d
0 
0 C A 
C/
T 
T 
C/
G 
C G G A C C A C A C C C T A G A/C T G/T G – 4 M 2 [1, 2] 0.8341 
19d
42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
response 
– – – – – 
1Ad
0 
0 T A C T 
C/
G 
C/
G 
G G 
A/
T 
C/T C G C/T A A A/C C/T A A G A/C C/T G/T G – 10 M 2 [2, 3] 0.7645 
1Ad
42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
– – – – – 
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response 
1d0 0 T A C T C C A G A T T G C/T A A C C A A G A/C T G/T G – 3 M 2 [1, 2] 0.8189 
1d4
2 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
response 
– – – – – 
21d
0 
0 C A C T C C A G T C T A C A A C T A A G C C T G – 0 S 1 [1, 1] 1.0000 
21d
42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
response 
– – – – – 
22d
0 
0 T G C C C C G G T C C A C A A C C A A A C C T G – 0 S 1 [1, 1] 1.0000 
22d
42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
response 
– – – – – 
23d
0 
0 T A C T C C A A A C C A C A A A/C C A A G C C G/T G – 2 M 1 [1, 1] 0.9920 
23d
42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
response 
– – – – – 
24d
0 
0 T A T T C C A G A C T G T C A C C T C G C T T G – 0 S 1 [1, 1] 1.0000 
24d
42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
response 
– – – – – 
25d
0 
0 C A C T C C A G A T T G C A A C T A C G A C T G – 0 S 1 [1, 1] 1.0000 
25d
42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
response 
– – – – – 
26d 0 C A C T C G A A A T T A C C C A T T A G C T T G – 0 S 1 [1, 1] 1.0000 
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0 
26d
42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
response 
– – – – – 
27d
0 
0 C A C T C C A G A T C G T A C C T A A G C T T G – 0 S 1 [1, 1] 1.0000 
27d
42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
response 
– – – – – 
28d
0 
0 – G 
C/
T 
C C C 
A/
G 
G 
A/
T 
T C A T C C A/C C T A A/G C C T G – 5 M 2 [1, 2] 0.8329 
28d
42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
response 
– – – – – 
29d
0 
0 T A C T C C A G A T C A C C C C C A A G A T G G – 0 S 1 [1, 1] 1.0000 
29d
42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
response 
– – – – – 
2Ad
0 
0 T A C 
C/
T 
C C A G A T C A C C C C C A A A/G A T T G – 2 M 1 [1, 1] 0.9903 
2Ad
42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
response 
– – – – – 
33d
0 
0 T A T T C G A G A T C A C A A A C T A G A/C C T G – 1 S 1 [1, 1] 0.9998 
33d
42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
response 
– – – – – 
34d
0 
0 T A C 
C/
T 
C 
C/
G 
A G 
A/
T 
C/T C/T A/G C/T A/C A/C A/C C/T A A/C G A/C C/T T G – 14 M 3 [3, 5+] 0.4759 
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34d
42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
response 
– – – – – 
35d
0 
0 T A C 
C/
T 
C/
G 
C/
G 
A/
G 
G A T C/T A/G C/T A C A/C T A/T A A/G A/C T T G – 11 M 2 [2, 3] 0.5896 
35d
42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
response 
– – – – – 
36d
0 
0 
C/
T 
A C T C G A A A T T A C A A/C C C/T A C G A T T G – 3 M 1 [1, 2] 0.6725 
36d
42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
response 
– – – – – 
38d
0 
0 T A T T C G A G A C T A T A A C C A A G A T G G – 0 S 1 [1, 1] 1.0000 
38d
42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
response 
– – – – – 
39d
0 
0 T A C T C C 
A/
G 
G T C/T C A C A C C C T A G A/C T T G – 3 M 1 [1, 2] 0.6289 
39d
42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
response 
– – – – – 
3Ad
0 
0 T A C T C 
C/
G 
A G 
A/
T 
T C G C A C C C A A A/G C C/T T G – 4 M 2 [2, 2] 0.9651 
3Ad
42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
response 
– – – – – 
3d0 0 C A C 
C/
T 
C C 
A/
G 
G A C/T T A C/T A A/C A/C C T A G A/C C/T T G – 8 M 2 [2, 3] 0.9287 
3d4 42 – – – – – – – – – – – – – – – – – – – – – – – – Adequate – – – – – 
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ical 
response 
41d
0 
0 T A C T C G G G A T T G T C A A C A/T A/C G A/C C T G – 3 M 1 [1, 2] 0.8034 
41d
42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
response 
– – – – – 
42d
0 
0 C G C T C C A G A C T A T C C C C A A A A T G G – 0 S 1 [1, 1] 1.0000 
42d
42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
response 
– – – – – 
43d
0 
0 T A 
C/
T 
T 
C/
G 
G 
A/
G 
G T T C A T A C C C/T T A G A/C C/T T G – 6 M 2 [2, 2] 0.9957 
43d
42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
response 
– – – – – 
44d
0 
0 C 
A/
G 
C 
C/
T 
C/
G 
C 
A/
G 
G T C/T C/T A C A A/C A C/T A/T A A/G A/C C G/T G – 12 M 2 [2, 4] 0.6187 
44d
42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
response 
– – – – – 
45d
0 
0 C A C C C 
C/
G 
A/
G 
G 
A/
T 
C/T T A/G C/T A C C T A A G C C/T T G – 7 M 2 [2, 2] 0.9799 
45d
42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
response 
– – – – – 
46d
0 
0 T A T T G G A G A C T A C A A C C T A G A T T G – 0 S 1 [1, 1] 1.0000 
46d
42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
– – – – – 
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50d
0 
0 T A 
C/
T 
T C 
C/
G 
A/
G 
G A T C/T G T A C C C A/T A G C T G/T G – 6 M 2 [2, 2] 0.9830 
50d
42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
response 
– – – – – 
51d
0 
0 C A C T G C G G T T T A T A A C C A A A C C T G – 0 S 1 [1, 1] 1.0000 
51d
42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
response 
– – – – – 
52d
0 
0 C A C T C C G G A T T G C C A C T T A A A/C T G G – 1 S 1 [1, 1] 0.9998 
52d
42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
response 
– – – – – 
54d
0 
0 T A C 
C/
T 
C/
G 
C A G 
A/
T 
C/T C G C/T A/C C C C A/T C A/G A/C C/T G/T G – 11 M 2 [2, 3] 0.6454 
54d
42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
response 
– – – – – 
58d
0 
0 T A C T 
C/
G 
C 
A/
G 
G A T C/T G C/T A A A/C C A A A/G A/C T G/T G – 8 M 2 [2, 3] 0.8987 
58d
42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
response 
– – – – – 
65d
0 
0 C A C T C G G G A C T G T A A C C A A A C T T G – 0 S 1 [1, 1] 1.0000 
65d
42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
– – – – – 
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66d
0 
0 T A C T C C 
A/
G 
A/
G 
A/
T 
C/T C A/G C A/C C A C/T A/T A G A C/T G/T G – 10 M 2 [2, 3] 0.8352 
66d
42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
response 
– – – – – 
67d
0 
0 T 
A/
G 
C/
T 
T 
C/
G 
C/
G 
A/
G 
G A C/T T A C/T A/C A A/C C/T A/T A A/G A/C C/T T G – 14 M 3 [2, 5+] 0.5520 
67d
42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
response 
– – – – – 
68d
0 
0 T A C C C C A G A C C A T A C C C A/T A/C G A/C C G G – 3 M 1 [1, 2] 0.8726 
68d
42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
response 
– – – – – 
69d
0 
0 T 
A/
G 
C 
C/
T 
C/
G 
C/
G 
A G A C/T C A/G C/T A/C C C C A/T A A/G C T G/T G – 11 M 2 [2, 3] 0.6565 
69d
42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
response 
– – – – – 
6d0 0 T A C T C C G G A C T G C A A A T T C G C T T G – 0 S 1 [1, 1] 1.0000 
6d4
2 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
response 
– – – – – 
70d
0 
0 C A C T C C G G A C T G C A C C C A C G C T T G – 0 S 1 [1, 1] 1.0000 
70d
42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
response 
– – – – – 
73d 0 T A C T C C G G A C T A C A A A T A/T C A A C/T G G – 2 M 1 [1, 1] 0.9973 
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73d
42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
response 
– – – – – 
74d
0 
0 T A C C C G A G A T – G C A A C C A A G C T G G – 0 S 1 [1, 1] 1.0000 
74d
42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
response 
– – – – – 
75d
0 
0 T A C T C C A G A C C G C A A C T A A G A C G G – 0 S 1 [1, 1] 1.0000 
75d
42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
response 
– – – – – 
76d
0 
0 T A C T C 
C/
G 
A/
G 
G A C/T C/T A/G C A/C C C C/T A/T A A/G A/C C/T T G – 11 M 3 [2, 4] 0.5806 
76d
42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
response 
– – – – – 
77d
0 
0 T A C T C G G G A T C A C A A C C A C G A T T G – 0 S 1 [1, 1] 1.0000 
77d
42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
response 
– – – – – 
78d
0 
0 C A C T C C G G A T T G C C A A T T A A C C T G – 0 S 1 [1, 1] 1.0000 
78d
42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
response 
– – – – – 
79d
0 
0 T A C T C G G G A C T G C A C C C T A G C C T G – 0 S 1 [1, 1] 1.0000 
Page 25 of 39 
79d
42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
response 
– – – – – 
7d0 0 T A C T C C A G A C C G C C C C C A A G A T G G – 0 S 1 [1, 1] 1.0000 
7d4
2 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
response 
– – – – – 
80d
0 
0 T A C T G C A G 
A/
T 
C/T T G T A C C T T C G C C/T T G – 3 M 1 [1, 2] 0.8769 
80d
42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
response 
– – – – – 
82d
0 
0 T A C T C C A G A T C A C C C C C A A G C T T G – 0 S 1 [1, 1] 1.0000 
82d
42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
response 
– – – – – 
83d
0 
0 T A C T C C G G A C C G C A C C T A C G A T T G – 0 S 1 [1, 1] 1.0000 
83d
42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
response 
– – – – – 
84d
0 
0 C A T T C G A G A T – A C A A C T A C G A T T G – 0 S 1 [1, 1] 1.0000 
84d
42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
response 
– – – – – 
85d
0 
0 C A C T C G G G T C C G C A C C C T A A C C T G – 0 S 1 [1, 1] 1.0000 
85d
42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
– – – – – 
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86d
0 
0 T A C T C G G A A C C G C A C C T T C A C C T G – 0 S 1 [1, 1] 1.0000 
86d
42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
response 
– – – – – 
90d
0 
0 T A C C C 
C/
G 
A 
A/
G 
A C/T C G C A/C C C C/T A/T A G C T T G – 6 M 2 [2, 2] 0.9892 
90d
42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
response 
– – – – – 
91d
0 
0 T 
A/
G 
C T 
C/
G 
C/
G 
A/
G 
A/
G 
A/
T 
C/T C/T A/G C A/C A/C C T A A A/G A/C T G/T G – 14 M 3 [2, 5+] 0.5631 
91d
42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
response 
– – – – – 
92d
0 
0 C A C 
C/
T 
C G 
A/
G 
A/
G 
A C T G C C C A/C C/T A A/C A/G A/C C/T T G – 9 M 2 [2, 3] 0.9487 
92d
42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
response 
– – – – – 
93d
0 
0 T A T T C C 
A/
G 
A A T T A T A A A C T A G C C T G – 1 S 1 [1, 1] 0.9999 
93d
42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
response 
0 – – – – 
95d
0 
0 
C/
T 
A 
C/
T 
C/
T 
C 
C/
G 
A/
G 
G A C/T C/T G C/T A/C C C C A/T A/C A/G A/C C/T G/T G – 15 M 4 [3, 5+] 0.4350 
95d
42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
– – – – – 
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96d
0 
0 T A C T C C A G 
A/
T 
T C A C C C A T A/T C A/G A/C C T G – 4 M 2 [2, 1] – 
96d
42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
response 
– – – – – 
97d
0 
0 – – C – C – G – A C/T T G C A – A C T A/C G C T G/T G – 3 M 2 [1, 2] 0.8524 
97d
42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
response 
– – – – – 
99d
0 
0 T A 
C/
T 
T C C 
A/
G 
G A T T G C C C C C A A G C C T G – 2 M 1 [1, 1] 1.0000 
99d
42 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
response 
– – – – – 
9d0 0 C A C T C C G G A T T G T C A A T T A G C T T G – 0 S 1 [1, 1] 1.0000 
9d4
2 
42 – – – – – – – – – – – – – – – – – – – – – – – – 
Adequate 
parasitolog
ical 
response 
– – – – – 
DD
2 
N/
A 
T A T C C G G A T T T A T C A A T A C A A C G T N/A 0 S 1 [1, 1] 1.0000 
HB3 
N/
A 
T G C C C C A G A T C A C A A C T A A G T T T T N/A 0 S 1 [1, 1] 1.0000 
K1 
N/
A 
C G C T C G G A T T T A T C C C T A C G C C G T N/A 0 S 1 [1, 1] 1.0000 
R03
3 
N/
A 
C A T T G C A G A C T – C A C C T T A G A T T G N/A 0 S 1 [1, 1] 1.0000 
W2 
N/
A 
T A T C C G G A T T T A T C A A T A C A A C G T N/A 0 S 1 [1, 1] 1.0000 
3D7 
N/
A 
C G C T C C G G A C T G C A C C C A A G A T T G N/A 0 S 1 [1, 1] 1.0000 
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msp-1 = merozoite surface protein 1; msp-2 = merozoite surface protein 2; N/A = not applicable; SNP = single-nucleotide polymorphism. For each patient, both 
the d0 and d42 filter paper samples were genotyped using the 24-SNP Barcoding Assay (Daniels et al.).
7
 Because d42 samples for these patients did not have 
detectable parasite DNA, these patients were deemed to have achieved “adequate parasitological response.” Only data for 71 patients with no detectable d42 
parasitemia are shown. “–” denotes that an allele was not detected. Number of heterozygous SNPs is the number of loci out of the 24 genotyped that carry both 
alternate SNP alleles. Clonality denotes the genetic complexity of an infection, that is, whether the infection contains multiple-parasite haplotypes (M) or a 
single-parasite haplotype (S). MOI = multiplicity of infection as determined by the maximum likelihood method called COIL (Galinsky et al.).
17
 Twelve SNPs 
highlighted in blue are proposed for the abbreviated SNP assay. Highlighted in green at the bottom of the table are SNP data for laboratory control parasites 
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SUPPLEMENTAL TABLE 4 
Msp-1 and msp-2 genotype data for patients with no detectable d42 parasitaemia 
Patient 
ID 
Day 
MA
D 20 
MAD 
20 
fragmen
t size 
K
1 
K1 
fragmen
t size 
RO3
3 
R033 
fragmen
t size 
3D7/I
C 
3D7/IC 
fragmen
t size 
FC2
7 
FC27 
fragmen
t size 
Treatment 
outcome 
Clonalit
y 
MO
I 
100d0 0 † 200 †† 200; 300 – – † 600 †† 300; 350 – M 2 
100d4
2 
42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
101d0 0 † 300 – – – – † 500 – – – S 1 
101d4
2 
42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
102d0 0 † 200 † 300 – – † 500 † 400 – M 2 
102d4
2 
42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
104d0 0 † 250 † 300 – – †† 400; 500 †† 300; 350 – M 2 
104d4
2 
42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
105d0 0 † 300 – – – – † 600 – – – M 2 
105d4
2 
42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
106d0 0 † 200 – – – – † 500 – – – S 1 
106d4
2 
42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
13d0 0 – – – – – – †† 550; 650 † 300 – M 2 
13d42 42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
14d0 0 – – – – † 160 † 550 – – – S 1 
14d42 42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
15d0 0 – – – – † 150 † 500 † 350 – M 2 
15d42 42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
19d0 0 † 300 – – – – † 500 † 450 – M 2 
19d42 42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
1Ad0 0 – – †† 200; 300 – – † 500 †† 250; 350 – M 2 
1Ad42 42 – – – – – – – – – – 
Adequate 
parasitologica
– – 
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1d0 0 † 200 – – – – † 500 † 300 – M 2 
1d42 42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
21d0 0 – – – – † 160 † 600 – – – S 1 
21d42 42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
22d0 0 – – † 200 – – – – † 450 – S 1 
22d42 42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
23d0 0 – – † 150 – – † 600 † 250 – M 2 
23d42 42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
24d0 0 † 200 – – – – – – † 400 – S 1 
24d42 42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
25d0 0 † 300 † 200 – – – – † 250 – M 2 
25d42 42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
26d0 0 – – – – † 160 † 600 – – – S 1 
26d42 42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
27d0 0 – – – – † 160 – – † 250 – S 1 
27d42 42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
28d0 0 – – †† 200; 250 – – †† 400; 500 – – – M 2 
28d42 42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
29d0 0 – – † 200 – – – – †† 250; 300 – M S 
29d42 42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
2Ad0 0 † 200 † 250 – – † 500 † 350 – M 2 
2Ad42 42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
33d0 0 † 200 – – – – † 500 – – – S 1 
33d42 42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
34d0 0 – – – – † 180 † 600 † 400 – M 2 
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34d42 42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
35d0 0 †† 200; 250 †† 200; 300 – – † 500 †† 350; 400 – M 2 
35d42 42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
36d0 0 † 300 – – – – † 500 †† 300; 400 – M 2 
36d42 42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
38d0 0 – – † 150 – – – – † 300 – S 1 
38d42 42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
39d0 0 † 200 – – – – † 550 † 400 – M 2 
39d42 42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
3Ad0 0 † 200 † 300 – – † 500 – – – M 2 
3Ad42 42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
3d0 0 † 200 †† 200; 300 – – † 550 † 350 – M 2 
3d42 42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
41d0 0 – – † 200 – – † 500 † 400 – M 2 
41d42 42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
42d0 0 † 200 – – – – – – † 400 – S 1 
42d42 42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
43d0 0 † 200 † 250 – – † 550 † 350 – M 2 
43d42 42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
44d0 0 † 250 † 200 – – – – † 400 – M 2 
44d42 42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
45d0 0 † 200 – – – – † 500 – – – S 1 
45d42 42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
46d0 0 † 200 – – – – † 500 – – – S 1 
46d42 42 – – – – – – – – – – 
Adequate 
parasitologica
– – 
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l response 
50d0 0 † 200 † 300 – – † 500 – – – M 2 
50d42 42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
51d0 0 – – † 250 – – † 500 – – – S 1 
51d42 42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
52d0 0 † 200 – – – – – – † 300 – S 1 
52d42 42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
54d0 0 †† 200; 250 † 200 – – † 600 † 300 – M 2 
54d42 42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
58d0 0 † 200 † 300 – – † 500 †† 300; 400 – M 2 
58d42 42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
65d0 0 †† 200; 300 † 300 – – † 500 † – – M 2 
65d42 42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
66d0 0 – – † 200 – – † 500 † 300 – M 2 
66d42 42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
67d0 0 †† 200; 300 † 200 – – † 500 † 350 – M 2 
67d42 42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
68d0 0 – – † 250 – – † 500 † 700 – M 2 
68d42 42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
69d0 0 † 200 – – – – – – † 350 – S 1 
69d42 42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
6d0 0 † 200 – – – – †† 400; 500 – – – M 2 
6d42 42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
70d0 0 – – † 200 – – † 500 – – – S 1 
70d42 42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
73d0 0 † 250 † 300 – – † 500 † 600 – M 2 
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73d42 42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
74d0 0 – – † 200 – – † 500 – – – M 2 
74d42 42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
75d0 0 – – † 300 – – – – † 400 – S 1 
75d42 42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
76d0 0 † 200 † 300 – – † 500 – – – M 2 
76d42 42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
77d0 0 † 300 † 300 – – – – † 400 – M 2 
77d42 42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
78d0 0 – – – – † 160 †† 500; 600 – – – M 2 
78d42 42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
79d0 0 – – † 200 – – † 500 – – – S 1 
79d42 42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
7d0 0 – – † 200 – – †† 500 – – – M 2 
7d42 42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
80d0 0 † 200 – – – – † 500 † 600 – M 2 
80d42 42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
82d0 0 † 300 † 250 – – † 500 † 350 – M 2 
82d42 42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
83d0 0 † 200 – – – – † 500 – – – S 1 
83d42 42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
84d0 0 – – † 200 – – † 500 – – – S 1 
84d42 42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
85d0 0 † 250 – – – – † 500 – – – S 1 
85d42 42 – – – – – – – – – – 
Adequate 
parasitologica
– – 
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l response 
86d0 0 – – † 300 – – – – † 400 – S 1 
86d42 42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
90d0 0 – – † 200 – – – – † 300 – S 1 
90d42 42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
91d0 0 – – †† 180; 240 – – †† 500; 550 † 300 – M 2 
91d42 42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
92d0 0 – – † 200 – – †† 400; 600 † 350 – M 2 
92d42 42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
93d0 0 – – – – † 160 † 400 – – – S 1 
93d42 42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
95d0 0 † 200 † 180 – – † 500 – – – M 2 
95d42 42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
96d0 0 † 300 – – – – † 500 – – – S 1 
96d42 42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
97d0 0 – – † 200 – – †† 500; 600 – – – M 2 
97d42 42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
99d0 0 – – † 250 – – † 500 † 300 – M 2 
99d42 42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
9d0 0 – – – – † 160 †† 500 – – – S 1 
9d42 42 – – – – – – – – – – 
Adequate 
parasitologica
l response 
– – 
DD2 
N/
A 
† 220 – – – – – – † 400 N/A S 1 
HB3 
N/
A 
† 180 – – – – – – † 300 N/A S 1 
K1 
N/
A 
– – † 180 – – – – † 380 N/A S 1 
R033 
N/
A 
– – – – † 160 † 480 – – N/A S 1 
W2 N/ † 220 – – – – – – † 400 N/A S 1 
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A 
3D7 
N/
A 
– – † 250 – – † 500 – – N/A S 1 
msp-1 = merozoite surface protein 1; msp-2 = merozoite surface protein 2. For each patient, both the d0 and d42 
filter paper samples were genotyped at msp-1 and msp-2 loci (Snounou et al.).
2
 Only data for 71 patients with no 
detectable d42 parasitaemia are shown. “†” denotes that one allele is present at a locus, whereas “–” shows that it is 
absent. If two alleles are present, the data are shown as “††,” “†††” if three are present, etc. Allele size is the 
approximate molecular size in bp of an msp-1 or msp-2 fragment detected. Because d42 samples for these patients 
did not have detectable parasite DNA, these patients were deemed to have achieved “adequate parasitological 
response.” Clonality denotes the genetic complexity of an infection, that is, whether the infection contains multiple-
parasite haplotypes (M) or a single-parasite haplotype (S). N/A = not applicable. Multiplicity of infection (MOI) is 
an estimate of the minimum number of parasite haplotypes present within an infection and was determined as the 
highest number of alleles observed at the most diverse locus. Highlighted in green at the bottom of the table are msp-
1 and msp-2 genotype data for laboratory control parasites. 
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